| Identification | Back Directory | [Name]
1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)-, mixt. with (3R,6S)-2-hydroxy-3-[[2-(2-thienyl)acetyl]amino]-1,2-oxaborinane-6-acetic acid | [CAS]
2031124-72-6 | [Synonyms]
Vabomere
Carbavance
Meropenem/vaborbactam
1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)-, mixt. with (3R,6S)-2-hydroxy-3-[[2-(2-thienyl)acetyl]amino]-1,2-oxaborinane-6-acetic acid | [Molecular Formula]
C29H41BN4O10S2 | [MOL File]
2031124-72-6.mol | [Molecular Weight]
680.6 |
| Hazard Information | Back Directory | [Description]
Carbavance is a mixture of meropenem and vaborbactam for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. | [Uses]
Meropenem-vaborbactam is an antibiotic against nonfermenting Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistant and carbapenemase genotypes[1]. | [References]
[1] Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae |
|
|